Floyd Robert Michael 4
4 · Processa Pharmaceuticals, Inc. · Filed Apr 4, 2022
Insider Transaction Report
Form 4
Floyd Robert Michael
Chief Operating Officer
Transactions
- Award
Restricted Stock Units
2021-11-01+4,286→ 27,066 totalExercise: $0.00→ Common Stock (4,286 underlying) - Award
Restricted Stock Units
2022-03-31+10,715→ 37,781 totalExercise: $0.00→ Common Stock (10,715 underlying) - Gift
Common Stock
2022-03-31−7,000→ 70,930 total
Holdings
- 66,345(indirect: by Elion Oncology, Inc.)
Common Stock
Footnotes (2)
- [F1]Shares previously reported as indirectly held by Elion Oncology were transferred to the reporting person's direct holdings in an transaction exempt from Section 16 reporting.
- [F2]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.